Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Carfilzomib in Refractory Multiple Myeloma
NCT03201250Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Feb 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in multiple myeloma (MM), sponsored by University of Nebraska. Started Feb 2018; status: terminated.
02
Drugs
cabozantinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03201250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201250.